Importantly, though the screening was initially conducted on a RET/PTC1-positive cell line (TPC1), subsequent validation experiments proved that sensitivity to knock-down of the 14 genes was shared by most thyroid cancer cell lines harboring different oncogenic lesions (BRAF mutation in BCPAP and 8505C and KRAS mutation in CAL62). This evidence concerns the gene KRAS and thyroid gland carcinoma.